Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.58 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711266 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29714923 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29496718 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29456901 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL10928123 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29898192 | 0.97 | ERAP2 (0.56) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29714947 | 0.96 | ERAP2 (0.55) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL30785147 | 0.96 | ERAP2 (0.55) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29543277 | 0.95 | ERAP2 (0.54) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL31287939 | 0.95 | ERAP2 (0.54) | ERAP2ERAP1LNPEPCPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100522249-C | Elongated multiple spacers in activatable prodrugs | SINTAGAR B V (NL) | 2009-08-05 | — | — | CN | claimed |
| CN-1511044-A | Elogated and multiple spacers in activatible prodrugs | — | 2004-07-07 | — | — | CN | claimed |
| WO-2026090562-A1 | DNA VECTORS HAVING SPECIALIZED SECONDARY STRUCTURES FOR USE IN TREATING HYPOPHOSPHATASIA | RAMPART BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089719-A1 | DNA VECTORS HAVING SPECIALIZED SECONDARY STRUCTURES FOR USE IN TREATING HYPOPHOSPHATASIA | RAMPART BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250360169-A1 | EXTRACELLULAR VESICLES AND METHODS OF USING | NUTECH VENTURES (US) | 2025-11-27 | — | — | US | disclosed |
| US-12290533-B2 | Extracellular vesicles and methods of using | NUTECH VENTURES (US) | 2025-05-06 | — | — | US | disclosed |
| US-11883434-B2 | Extracellular vesicles and methods of using | NUTECH VENTURES (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230124955-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4074694-A1 | AMINO ACID-, PEPTIDE- AN POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AN USES THEREOF | Massachusetts Institute Of Technology (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | disclosed |
| US-20220031851-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| CN-100522249-C | Elongated multiple spacers in activatable prodrugs | SINTAGAR B V (NL) | 2009-08-05 | — | — | CN | disclosed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1909846-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION | Syntarga B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| US-4256632-A | ANTICAREINOGENIC AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | ERAP2 3834/4885ERAP1 2713/4885LNPEP 1800/4885 |
| US-20220031851-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | ERAP2 1321/4885ERAP1 1723/4885LNPEP 1381/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | ERAP2 3376/4885ERAP1 2891/4885LNPEP 602/4885 |
| US-20230124955-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | ERAP2 535/4885ERAP1 472/4885LNPEP 11/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | ERAP2 4123/4885ERAP1 3187/4885LNPEP 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.